Dr. Korentzelos currently serves as Assistant Professor of Pathology at the Genitourinary Pathology Center of Excellence at UPMC Shadyside. Dr. Korentzelos received his medical degree from the University of Patras, School of Medicine, in 2013, and completed a year of pathology residency at the General University Hospital of Patras. Subsequently, he worked as a postdoctoral research fellow at the University of Texas MD Anderson Cancer Center for two years before joining the Pathologist Investigator Residency / Research Training Program (PIRRT) at UPMC / University of Pittsburgh. Finally, he pursued a Genitourinary Pathology fellowship at UPMC and was a member of Pitt-UPMC Senior Resident and Fellow Leadership Academy.
Dr. Korentzelos’ research interests revolve around genitourinary malignancies, including mechanisms of lineage plasticity in neuroendocrine prostate cancer and immunotherapy in castration-resistant prostate cancer. More recent endeavors focus on the clinical use of artificial intelligence-based algorithms in prostate cancer diagnosis, quantitative image analysis for predicting response to BCG treatment in non-muscle invasive bladder cancer, and next-generation sequencing studies in urothelial carcinoma and renal cell carcinoma.
· Diamantopoulos LN, Makrakis D, Korentzelos D, Alevizakos M, Wright JL, Grivas P, Bountziouka V, Vadikolias K, Lambropoulou M, Tripsianis G. Development and validation of a prognostic nomogram for overall and disease-specific survival in patients with sarcomatoid urothelial carcinoma. Urol Oncol. 2023 Mar 15:S1078-1439(23)00046-7. doi: 10.1016/j.urolonc.2023.01.019. Online ahead of print.
· Rammal R, Korentzelos D, Skaugen JM, Quiroga-Garza GM. Molecular Characterization of Malignant Renal Epithelioid Angiomyolipoma: A Review of Two Cases. Am J Clin Pathol. 2023 Mar 13;159(3):211-220. doi: 10.1093/ajcp/aqac152.
· Korentzelos D, Elishaev E, Zhao C, Jones MW, Soong TR, Lesnock J, Orellana T, Zeccola A, Diamantopoulos LN, Wald AI, Bhargava R. ARID1A, BRG1, and INI1 deficiency in undifferentiated and dedifferentiated endometrial carcinoma: a clinicopathologic, immunohistochemical, and next-generation sequencing analysis of a case series from a single institution. Hum Pathol. 2022 Dec;130:65-78. doi: 10.1016/j.humpath.2022.10.003. Epub 2022 Oct 14.
· Korentzelos D, Wells A, Clark AM. Interferon-γ increases sensitivity to chemotherapy and provides immunotherapy targets in models of metastatic castration-resistant prostate cancer. Sci Rep. 2022 Apr 22;12(1):6657. doi: 10.1038/s41598-022-10724-9.
· Korentzelos D, Baloda V, Jung Y, Wheeler B, Shurin MR, Wheeler SE. COVID-19 mRNA Vaccines May Cause False Reactivity in Some Serologic Laboratory Tests, Including Rapid Plasma Reagin Tests. Am J Clin Pathol. 2022 Mar 30:aqac025. doi: 10.1093/ajcp/aqac025. Online ahead of print.
· Korentzelos D, Clark AM, Wells A. Perspective on Therapeutic Pan-Resistance in Metastatic Cancer. Int J Mol Sci. 2020 Oct 3;21(19):7304. doi: 10.3390/ijms21197304.
· Liu B, Li L, Yang G, Geng C, Luo Y, Wu W, Manyam GC, Korentzelos D, Park S, Tang Z, Wu C, Dong Z, Sigouros M, Sboner A, Beltran H, Chen Y, Corn PG, Tetzlaff MT, Troncoso P, Broom B, Thompson TC. PARP Inhibition Suppresses GR–MYCN–CDK5–RB1–E2F1 Signaling and Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer. Clin Cancer Res. 2019 Nov 15;25(22):6839-6851. doi: 10.1158/1078-0432.CCR-19-0317. Epub 2019 Aug 22.
· Luo Y, Azad AK, Karanika S, Basourakos SP, Zuo X, Wang J, Yang L, Yang G, Korentzelos D, Yin J, Park S, Zhang P, Campbell JJ, Schall TJ, Cao G, Li L, Thompson TC. Enzalutamide and CXCR7 inhibitor combination treatment suppresses cell growth and angiogenic signaling in castration-resistant prostate cancer models. Int J Cancer. 2018 May 15;142(10):2163-2174. doi: 10.1002/ijc.31237. Epub 2018 Jan 30.
· Zhang W, Liu B, Wu W, Li L, Broom BM, Basourakos SP, Korentzelos D, Luan Y, Wang J, Yang G, Park S, Azad AK, Cao X, Kim J, Corn PG, Logothetis CJ, Aparicio AM, Chinnaiyan AM, Navone N, Troncoso P, Thompson TC. Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate Cancer. Clin Cancer Res. 2018 Feb 1;24(3):696-707. doi: 10.1158/1078-0432.CCR-17-1872. Epub 2017 Nov 14.
· Li L, Karanika S, Yang G, Wang J, Park S, Broom BM, Manyam GC, Wu W, Luo Y, Basourakos S, Song JH, Gallick GE, Karantanos T, Korentzelos D, Azad AK, Kim J, Corn PG, Aparicio AM, Logothetis CJ, Troncoso P, Heffernan T, Toniatti C, Lee HS, Lee JS, Zuo X, Chang W, Yin J, Thompson TC. Androgen receptor inhibitor-induced "BRCAness" and PARP inhibition are synthetically lethal for castration-resistant prostate cancer. Sci Signal. 2017 May 23;10(480). pii: eaam7479. doi: 10.1126/scisignal.aam7479.